These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34569453)

  • 41. Vaccines against Meningococcal Diseases.
    Pizza M; Bekkat-Berkani R; Rappuoli R
    Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33022961
    [No Abstract]   [Full Text] [Related]  

  • 42. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.
    Guedes S; Bertrand-Gerentes I; Evans K; Coste F; Oster P
    BMC Public Health; 2022 Feb; 22(1):380. PubMed ID: 35197024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries.
    Valmas C; Arcà E; Hensen M; Rashid H
    Expert Rev Vaccines; 2022 Nov; 21(11):1637-1646. PubMed ID: 36222056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.
    Parikh SR; Campbell H; Bettinger JA; Harrison LH; Marshall HS; Martinon-Torres F; Safadi MA; Shao Z; Zhu B; von Gottberg A; Borrow R; Ramsay ME; Ladhani SN
    J Infect; 2020 Oct; 81(4):483-498. PubMed ID: 32504737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
    Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y
    Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
    Carr JP; MacLennan JM; Plested E; Bratcher HB; Harrison OB; Aley PK; Bray JE; Camara S; Rodrigues CMC; Davis K; Bartolf A; Baxter D; Cameron JC; Cunningham R; Faust SN; Fidler K; Gowda R; Heath PT; Hughes S; Khajuria S; Orr D; Raman M; Smith A; Turner DPJ; Whittaker E; Williams CJ; Zipitis CS; Pollard AJ; Oliver J; Morales-Aza B; Lekshmi A; Clark SA; Borrow R; Christensen H; Trotter C; Finn A; Maiden MC; Snape MD;
    Clin Microbiol Infect; 2022 Dec; 28(12):1649.e1-1649.e8. PubMed ID: 35840033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enter B and W: two new meningococcal vaccine programmes launched.
    Ladhani SN; Ramsay M; Borrow R; Riordan A; Watson JM; Pollard AJ
    Arch Dis Child; 2016 Jan; 101(1):91-5. PubMed ID: 26672098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
    Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS
    Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta.
    Pace D; Gauci C; Barbara C
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1885-1897. PubMed ID: 32418063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.
    Gruhn S; Batram M; Wick M; Langevin E; Scholz S; Greiner W; Damm O
    Infect Dis Ther; 2024 Apr; 13(4):907-920. PubMed ID: 38570446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.
    Martinón-Torres F; Serra L; Safadi MAP
    Expert Rev Vaccines; 2020 Apr; 19(4):313-325. PubMed ID: 32250710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.